Login to Your Account



CVT Deal Looking Better

Gilead's Darusentan Hits Phase III Endpoints

By Trista Morrison


Monday, April 6, 2009
Gilead Sciences Inc.'s recent move to diversify away from HIV and into cardiovascular disease by acquiring CV Therapeutics Inc. may get more investor support now that Gilead's internal cardiovascular pipeline appears to be panning out. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription